Petros Grivas Announced as Candidate for ASCO Nominating Committee

Petros Grivas Announced as Candidate for ASCO Nominating Committee

Petros Grivas, MD, PhD, FASCO, Professor at Fred Hutch Cancer Center and the University of Washington in Seattle, has been announced as a candidate for the American Society of Clinical Oncology (ASCO) Nominating Committee in the Undesignated Member category.

The election includes two available seats, each carrying a three-year term.

With a professional background spanning clinical oncology, academic research, international collaboration, and patient education, Dr. Grivas brings experience in several areas of ASCO’s scientific and organizational activities.

His current involvement as Chair-Elect of the ASCO Patient Information Advisory Committee and as a member of the TAPUR Scientific Advisory Group, alongside his previous service on the Society’s Annual Meeting committees, reflects his longstanding engagement with oncology research, education, and professional leadership.

Academic and Clinical Leadership at Fred Hutch Cancer Center

Dr. Grivas currently serves as Professor in the Clinical Research Division at Fred Hutch Cancer Center, where he also holds the positions of Medical Director of Local/Regional Outreach and Medical Director of the International Program.

In addition, he is a Professor in the Division of Hematology and Oncology at the University of Washington in Seattle.

These appointments connect academic oncology and clinical research with regional and international professional engagement.

At Fred Hutch Cancer Center, his leadership responsibilities extend to programs focused on outreach and international activities, reflecting the importance of collaboration between cancer institutions and healthcare professionals across different settings.

As oncology research continues to generate new treatment strategies and scientific evidence, communication and cooperation among institutions remain essential to advancing clinical practice.

Dr. Grivas’s academic and institutional roles place him within this environment, combining research-related responsibilities with broader engagement across the oncology community.

A Growing Leadership Role in Patient Information

One of Dr. Grivas’s current ASCO responsibilities is his position as Chair-Elect of the Patient Information Advisory Committee.

The committee contributes to the Society’s work in providing reliable, accessible, and clinically relevant cancer information for patients and their families.

Patient education is an important part of oncology care, particularly as treatment options become increasingly complex and patients are asked to participate in decisions involving multiple therapeutic approaches.

Clear communication can help patients better understand their diagnosis, available treatments, potential adverse effects, and the questions they may wish to discuss with their healthcare teams.

Through his role on the Patient Information Advisory Committee, Dr. Grivas is involved in ASCO’s efforts to support the communication of oncology information beyond the professional medical community.

His appointment as Chair-Elect represents an additional leadership responsibility within the Society’s patient-focused activities.

Contributing to Precision Oncology Through TAPUR

Dr. Grivas also currently serves as a member of the TAPUR Scientific Advisory Group.

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is an ASCO-sponsored clinical research initiative examining the use of targeted anticancer therapies in patients with advanced cancers that have specific genomic alterations.

The study is designed to generate evidence about the activity and safety of selected targeted treatments when used outside their approved indications in molecularly defined patient populations.

TAPUR reflects an important area of contemporary oncology research: understanding how genomic information may guide treatment decisions across different cancer types.

As molecular profiling becomes more widely incorporated into clinical care, research initiatives such as TAPUR contribute to evaluating the potential clinical relevance of genomic findings.

Dr. Grivas’s participation in the Scientific Advisory Group connects his ASCO service with research activities related to precision oncology and the development of evidence that may inform future treatment strategies.

Supporting Scientific Exchange and Oncology Education

Dr. Grivas has also contributed to ASCO through previous membership on the Annual Meeting Scientific Program Committee and Annual Meeting Education Program Committee.

The ASCO Annual Meeting is one of the largest international gatherings of oncology professionals, providing a platform for presenting clinical research, discussing emerging treatment approaches, and examining developments across cancer specialties.

The Scientific Program Committee plays a role in shaping the meeting’s research-focused content, while the Education Program Committee contributes to educational sessions intended to support professional learning and clinical practice.

Dr. Grivas’s service on both committees reflects his involvement in the scientific and educational dimensions of the Society’s work.

His participation has connected him with activities that support the exchange of research findings and the continuing education of oncology professionals worldwide.

Developing Leadership Within ASCO

In addition to his committee service, Dr. Grivas is a graduate of the ASCO Leadership Development Program.

The program is designed to support the professional growth of oncology leaders through structured educational experiences, mentorship, and exposure to the Society’s organizational activities.

Graduates of the program gain experience relevant to leadership within oncology institutions, professional organizations, and the broader cancer care community.

Dr. Grivas’s participation in the program adds to his experience across ASCO’s research, education, and patient information initiatives.

His subsequent involvement in advisory and committee positions reflects continued service within the Society.

The Role of the ASCO Nominating Committee

The ASCO Nominating Committee plays an important role in the Society’s leadership selection process.

The committee is responsible for identifying and evaluating candidates for designated ASCO leadership positions, helping support the process through which individuals are nominated for service within the organization.

Its work is an essential component of ASCO’s governance structure, contributing to leadership succession and representation across the oncology profession.

The Undesignated Member category allows candidates from different areas of oncology to participate in this process.

For the upcoming election, two seats are available, each with a three-year term.

Dr. Grivas’s candidacy brings together experience in academic oncology, clinical research, scientific programming, patient education, and professional leadership development.

A New Chapter in ASCO Service

Dr. Petros Grivas’s candidacy for the ASCO Nominating Committee represents a potential extension of his involvement in the Society’s scientific, educational, and advisory activities.

His leadership appointments at Fred Hutch Cancer Center, academic role at the University of Washington, and current responsibilities within the Patient Information Advisory Committee and TAPUR Scientific Advisory Group reflect his engagement with several aspects of oncology.

His previous service on the Annual Meeting Scientific and Education Program Committees, together with his completion of ASCO’s Leadership Development Program, further contributes to his professional background.

If elected, Dr. Grivas would serve a three-year term on the ASCO Nominating Committee, participating in the process of identifying and evaluating future leaders of the Society.

The election will determine the two representatives selected for the Undesignated Member seats as ASCO prepares for its upcoming leadership cycle.

More articles like this are available on OncoDaily.

Vahe Grigoryan
Fact checked by Vahe Grigoryan MD, Editorial Director
Vahe Grigoryan
Medically reviewed by Vahe Grigoryan MD, Editorial Director